Adjuvant radiotherapy gains phase III support in completely resected atypical meningioma
Patients with stage III atypical meningioma have long sat in a difficult postoperative middle ground. Surgery is standard, yet the value of adding radiotherapy after a complete resection has rested on weaker evidence than clinicians would ideally want for a treatment that carries real long-term consequences for brain tissue, cranial nerves, and quality of life. The phase III ROAM/EORTC-1308 trial now provides randomized evidence that adjuvant radiotherapy improves outcomes in this setting.
The trial enrolled 157 patients with surgeon-assessed completely resected atypical meningioma and assigned them in a 1:1 ratio to postoperative intensity-modulated external beam radiotherapy or observation. The radiation regimen was precise and conventional for a definitive postoperative approach: 60 Gy delivered in 30 fractions over 6 weeks. Disease-free survival served as the primary endpoint, making local and regional recurrence the central question rather than a narrow focus on immediate postoperative recovery.
One sentence captures the shift in practice logic: observation is no longer the only evidence-based default after complete resection.
Why postoperative control matters in atypical meningioma
Atypical meningiomas behave differently from the more indolent tumors that neurologists and neurosurgeons often associate with the broader meningioma category. Even after a surgeon achieves what appears to be a complete resection, microscopic residual disease can remain embedded at the dural margin or within adjacent tissue planes. That residual burden is exactly the kind of target that adjuvant radiotherapy is designed to sterilize.
Intensity-modulated external beam radiotherapy is particularly relevant here because conformal planning helps shape dose around the postoperative bed while limiting exposure to surrounding structures. In the skull base and other anatomically constrained regions, precision matters: the therapeutic goal is durable local control without exchanging a recurrent tumor for avoidable toxicity. The ROAM/EORTC-1308 design reflects that balance, using a standard fractionation schedule that fits established radiobiologic principles for slowly proliferating meningioma cells.
The trial’s value lies not only in the direction of the result, but in the fact that a randomized study now supports the strategy after years of reliance on non-comparative prospective series and retrospective analyses. For patients and clinicians, that distinction changes the confidence level behind postoperative decision-making.
A randomized answer to a long-running clinical debate
Before this trial, adjuvant radiotherapy for completely resected atypical meningioma remained a persistent gray zone. Many teams favored treatment because atypical histology signals a more aggressive biological behavior than grade 1 disease, yet the field lacked robust comparative evidence. Others preferred observation after what appeared to be a gross total resection, reserving radiation for recurrence and avoiding the long-term burden of treating every patient upfront.
ROAM/EORTC-1308 directly tested those competing strategies. By randomizing 157 patients between adjuvant radiotherapy and observation, the investigators addressed the exact choice clinicians face in the postoperative clinic. The study design also matters because it evaluates a real-world decision after surgery rather than an idealized laboratory scenario. That makes the result clinically portable, even before one gets to the details of individual risk factors or institutional preferences.
The primary endpoint of disease-free survival is appropriate for a tumor in which recurrence can drive repeat surgery, salvage radiation, and cumulative neurologic morbidity. A cleaner first remission is not a cosmetic endpoint in meningioma care; it can determine whether a patient avoids years of imaging anxiety, retreatment, and the loss of function that follows regrowth near eloquent brain regions.
Radiation dose, treatment burden, and bedside trade-offs
A 6-week course of radiotherapy is not trivial. Patients receive 30 fractions, which means repeated visits, time away from work or family responsibilities, and exposure to the cumulative burdens of treatment logistics. Those practical considerations often influence whether a clinician recommends postoperative radiation after apparent complete resection.
Yet the biology of atypical meningioma makes the treatment burden easier to justify once local control improves. A tumor that has already demonstrated more aggressive behavior than a typical grade 1 lesion is precisely the kind of lesion in which preventing recurrence can outweigh the short-term inconvenience of a defined radiotherapy course. The long runway of follow-up after meningioma surgery also means that a treatment decision made today can shape the patient’s course for years.
The ROAM/EORTC-1308 regimen uses intensity-modulated external beam radiotherapy, a technique selected to improve dose conformity. In the postoperative brain, that matters because normal tissue tolerance is finite and late toxicity can appear long after the treatment window has closed. A protocol built around careful fractionation and modern planning offers the clearest path to balancing tumor control against collateral injury.
What the phase III result changes now
The main clinical consequence is straightforward: after complete resection of atypical meningioma, adjuvant radiotherapy now has phase III support rather than extrapolated enthusiasm alone. For multidisciplinary teams, that strengthens the case for discussing postoperative irradiation as part of standard management rather than as an optional escalation reserved for the most worrisome cases.
The result also places greater weight on postoperative counseling. Patients need to understand that a complete resection does not erase the biologic risk carried by WHO grade 2 disease. Microscopic persistence can survive surgery, and recurrence can emerge despite an apparently successful operation. Radiation is aimed at that hidden disease burden.
Even with randomized support, individualized discussion still matters because the decision sits at the intersection of recurrence risk, expected toxicity, anatomic location, and patient priorities. Some patients will accept the effort of 6 weeks of treatment to reduce the chance of relapse. Others will prioritize observation and postpone intervention unless the tumor returns. The new evidence does not eliminate that conversation; it gives it a firmer evidentiary base.
The trial leaves one practical question for routine care: how best to integrate adjuvant radiotherapy into postoperative pathways across different centers, especially when local expertise, planning resources, and patient access vary. What the study does establish is narrower and more consequential—after complete resection of atypical meningioma, adjuvant radiotherapy has moved from plausible to proven within a randomized phase III framework.